JP5203644B2 - 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 - Google Patents
自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 Download PDFInfo
- Publication number
- JP5203644B2 JP5203644B2 JP2007184470A JP2007184470A JP5203644B2 JP 5203644 B2 JP5203644 B2 JP 5203644B2 JP 2007184470 A JP2007184470 A JP 2007184470A JP 2007184470 A JP2007184470 A JP 2007184470A JP 5203644 B2 JP5203644 B2 JP 5203644B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lupus erythematosus
- systemic lupus
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 58
- 150000001875 compounds Chemical class 0.000 title claims description 26
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims description 13
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 65
- -1 dimethoxy-6-methyl-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl) -cyclohex-2-enone Chemical compound 0.000 claims description 55
- 230000003460 anti-nuclear Effects 0.000 claims description 40
- 230000006378 damage Effects 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 210000003734 kidney Anatomy 0.000 claims description 24
- 230000002485 urinary effect Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- LJTSIMVOOOLKOL-UHFFFAOYSA-N 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-en-1-one Chemical compound COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CCC=C(C)C)C1O LJTSIMVOOOLKOL-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 7
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims description 6
- LJTSIMVOOOLKOL-JAXLGGSGSA-N antroquinonolTM Natural products COC1=C(OC)C(=O)[C@@H](C)[C@H](CC=C(C)CCC=C(C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-JAXLGGSGSA-N 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 3
- 229960003750 ethyl chloride Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 230000000116 mitigating effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 210000002700 urine Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 150000003431 steroids Chemical class 0.000 description 10
- 239000013642 negative control Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241001486992 Taiwanofungus camphoratus Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000000422 nocturnal effect Effects 0.000 description 7
- 150000003648 triterpenes Chemical class 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- TWXWPPKDQOWNSX-UHFFFAOYSA-N dicyclohexylmethanone Chemical compound C1CCCCC1C(=O)C1CCCCC1 TWXWPPKDQOWNSX-UHFFFAOYSA-N 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DVORYMAGXQGBQK-UHFFFAOYSA-N zhankuic acid A Natural products CC12CCC(=O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 DVORYMAGXQGBQK-UHFFFAOYSA-N 0.000 description 3
- RJXJHEYXZURDJH-UHFFFAOYSA-N 4,7-dimethoxy-5-methyl-1,3-benzodioxole Chemical compound COC1=CC(C)=C(OC)C2=C1OCO2 RJXJHEYXZURDJH-UHFFFAOYSA-N 0.000 description 2
- SDYJYMBMSYYZIC-UHFFFAOYSA-N 7,7-dimethyl-4-methylidene-3,3a,5,6,6a,8,9,10-octahydrobenzo[h][2]benzofuran-1-one Chemical compound C=C1CCC2C(C)(C)CCCC32C(=O)OCC31 SDYJYMBMSYYZIC-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 241000386860 Cinnamomum micranthum Species 0.000 description 2
- ONFPYGOMAADWAT-OXUZYLMNSA-N Dehydroeburicoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@@]4(C)C3=CC[C@H]21 ONFPYGOMAADWAT-OXUZYLMNSA-N 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000238413 Octopus Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexyloxide Natural products O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- WAAWMJYYKITCGF-ADGVWNIHSA-N ergostane group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CC[C@H](C)C(C)C WAAWMJYYKITCGF-ADGVWNIHSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 231100001028 renal lesion Toxicity 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229930009674 sesquiterpene lactone Natural products 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 210000002356 skeleton Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229930188837 zhankuic acid Natural products 0.000 description 2
- NDNKBYRXHKLSJQ-UXYVAYPWSA-N (2r)-2-[(3s,5r,10s,13r,14r,15s,17r)-15-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 NDNKBYRXHKLSJQ-UXYVAYPWSA-N 0.000 description 1
- DVORYMAGXQGBQK-HPRYJKPLSA-N (2s,6r)-2-methyl-3-methylidene-6-[(4s,5s,10s,13r,14r,17r)-4,10,13-trimethyl-3,7,11-trioxo-1,2,4,5,6,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-HPRYJKPLSA-N 0.000 description 1
- TWISSXUWVGIUBP-UHFFFAOYSA-N (4alpha,7beta)-7-Hyddroxy-4-methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TWISSXUWVGIUBP-UHFFFAOYSA-N 0.000 description 1
- PMHCHLYGCHPBEC-CYFVRWTGSA-N (6R)-2-methyl-3-methylidene-6-[(4S,10S,13R,17R)-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound O=C1[C@H](C2CCC=3C4=CC[C@H]([C@@H](CCC(C(C(=O)O)C)=C)C)[C@]4(CC(C=3[C@]2(CC1)C)=O)C)C PMHCHLYGCHPBEC-CYFVRWTGSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-GIMPTUAXSA-N (6r)-6-[(4s,7s,10s,13r,17r)-7-hydroxy-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methyl-3-methylideneheptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)C1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC=C21 ZPSJWLSADLCKBZ-GIMPTUAXSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NDNKBYRXHKLSJQ-UHFFFAOYSA-N 15alpha-acetyldehydrosulphurenic acid Natural products CC(C)C(=C)CCC(C1CC(OC(=O)C)C2(C)C3=CCC4C(C)(C)C(O)CCC4(C)C3=CCC12C)C(=O)O NDNKBYRXHKLSJQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WTSUWKBKPMVEBO-UHFFFAOYSA-N 4alpha-4-Methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CCC1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 WTSUWKBKPMVEBO-UHFFFAOYSA-N 0.000 description 1
- PMHCHLYGCHPBEC-UHFFFAOYSA-N Antcin E Natural products CC(CCC(=C)C(C)C(=O)O)C1CC=C2C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)C4CC3 PMHCHLYGCHPBEC-UHFFFAOYSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-UHFFFAOYSA-N Antcin F Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CC=C21 ZPSJWLSADLCKBZ-UHFFFAOYSA-N 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 0 C*C(C(C(C1CCC(CCC=C(C)*)N)O)=O)=C(*)C1O Chemical compound C*C(C(C(C1CCC(CCC=C(C)*)N)O)=O)=C(*)C1O 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- ONFPYGOMAADWAT-UHFFFAOYSA-N Dehydroeburicolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 ONFPYGOMAADWAT-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001391951 Guapira discolor Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZWMDJBNGXKAIRO-UHFFFAOYSA-N Methyl antcinate H Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)C(O)C2(C)C(C(C)CCC(=C)C(C)C(=O)OC)CCC21 ZWMDJBNGXKAIRO-UHFFFAOYSA-N 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001505935 Phalaenopsis Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- TXEJUZMIQVTZHO-UHFFFAOYSA-N Zhankuic acid B Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TXEJUZMIQVTZHO-UHFFFAOYSA-N 0.000 description 1
- LVFHKUZOQUATIE-UHFFFAOYSA-N Zhankuic acid C Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)C(O)C2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 LVFHKUZOQUATIE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- WTSUWKBKPMVEBO-QNMMDLTMSA-N antcin A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CCC1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 WTSUWKBKPMVEBO-QNMMDLTMSA-N 0.000 description 1
- TWISSXUWVGIUBP-IRXLFGEOSA-N antcin C Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 TWISSXUWVGIUBP-IRXLFGEOSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-BJLSYBTBSA-N antcin F Natural products C[C@H](CCC(=C)[C@H](C)C(=O)O)[C@H]1CC=C2C3=C(C(=O)C[C@]12C)[C@@]4(C)CCC(=O)[C@@H](C)[C@@H]4C[C@@H]3O ZPSJWLSADLCKBZ-BJLSYBTBSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- DVXFDXIVWQWLIU-UHFFFAOYSA-N dehydroeburiconic acid Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 DVXFDXIVWQWLIU-UHFFFAOYSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- ZQIOPEXWVBIZAV-ZKYCIREVSA-N lanostane Chemical group CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@@H]2[C@]2(C)CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 ZQIOPEXWVBIZAV-ZKYCIREVSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- ZWMDJBNGXKAIRO-PRBDMEKXSA-N methyl antcinate H Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)[C@H](O)[C@]2(C)[C@@H]([C@H](C)CCC(=C)C(C)C(=O)OC)CC[C@H]21 ZWMDJBNGXKAIRO-PRBDMEKXSA-N 0.000 description 1
- 229930183875 methylantcinate Natural products 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012144 protein assay dye reagent concentrate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003429 steroid acids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- DVORYMAGXQGBQK-QCMFUGJUSA-N zhankuic acid A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-QCMFUGJUSA-N 0.000 description 1
- TXEJUZMIQVTZHO-JNXQNPAGSA-N zhankuic acid B Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 TXEJUZMIQVTZHO-JNXQNPAGSA-N 0.000 description 1
- LVFHKUZOQUATIE-NIQDNRFFSA-N zhankuic acid C Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)[C@H](O)[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 LVFHKUZOQUATIE-NIQDNRFFSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
またYang氏等は二種のエルゴスタンを骨格とする新化合物zhankuic acid D、zhankuic acid Eと三種のラノスタン(lanostane)を骨格とする新化合物:15α−アセチル−デハイドロサルファレニック酸(15α−acetyl−dehydrosulphurenic acid)、デハイドロエブリコイック酸(dehydroeburicoic acid)とデハイドラサルファレニック酸(dehydrasulphurenic acid)(引用文献5)を発見した。
[引用文献2] Chen, C. H., and Yang, S. W. 1995. New steroid acids from Antrodiacinnamomea, −a fungus parasitic on Cinnamomum micranthum. J. Nat. Prod. 58:1655−1661
[引用文献3] Chiang, H. C., Wu, D. P., Cherng, I. W., and Ueng, C. H. 1995. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry. 39:613−616
[引用文献4] Cherng, I. H., Wu, D. P., and Chiang, H. C. 1996. Triteroenoids from Antrodia cinnamomea. Phytochemistry. 41:263−267
[引用文献5] Yang, S. W., Shen, Y. C., and Chen, C. H. 1996. Steroids and triterpenoids of Antrodiacinnamomea−a fungus parasitic on Cinnamomum micranthum. Phytochemistry. 41:1389−1392
請求項2の発明は、前記化合物はベニクスノキタケの有機溶剤抽出物中から分離製造することを特徴とする請求項1記載の自己免疫疾病治療に用いるベニクスノキタケのシクロヘキサンケトン抽出物としている。
請求項3の発明は、前記有機溶剤はエステル類、アルコール類、アルケン類或いはハロセンにより組成するグループから選択することを特徴とする請求項2記載の自己免疫疾病治療に用いるベニクスノキタケのシクロヘキサンケトン抽出物としている。
請求項4の発明は、前記アルコール類はエタノールであることを特徴とする請求項3記載の自己免疫疾病治療に用いるベニクスノキタケのシクロヘキサンケトン抽出物としている。
請求項5の発明は、前記化合物はベニクスノキタケの水抽出物中より分離製造することを特徴とする請求項1記載の自己免疫疾病治療に用いるベニクスノキタケのシクロヘキサンケトン抽出物としている。
請求項6の発明は、前記化合物は4−ハイドロキシ−2,3−ジメトキシ−6−メチル−5(3,7,11−トリメチル−ドデカ−2,6,10−トリエニル)−シクロヘキセ−2−エンオン(4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11- trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone)であることを特徴とする請求項1記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項7の発明は、前記化合物は自己免疫疾病が哺乳動物に対して引き起こす腎臓損傷及び自己免疫疾病が生成する抗核抗体の器官組織に対する傷害を緩和可能であることを特徴とする請求項1或いは請求項6記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項8の発明は、前記哺乳動物はヒトであることを特徴とする請求項7記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項9の発明は、前記自己免疫疾病は全身性エリテマトーデスであることを特徴とする請求項8記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項10の発明は、前記化合物は哺乳動物の尿タンパク含量を低下させることにより、全身性エリテマトーデスが引き起こす腎臓損傷を緩和することができることを特徴とする請求項9記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項11の発明は、前記化合物は哺乳動物血清中の抗核抗体含量を低下させ、全身性エリテマトーデスが引き起こす自己組織器官への損傷を緩和することができることを特徴とする請求項9記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項12の発明は、前記抗核抗体はダブルストランドDNAの抗核抗体であることを特徴とする請求項11記載の自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物としている。
請求項13の発明は、自己免疫疾病治療に用いる医薬組成物は少なくとも有効剤量の請求項1記載の化合物と医学上受け入れ可能なキャリアを含むことを特徴とする自己免疫疾病治療に用いる医薬組成物としている。
請求項14の発明は、前記自己免疫疾病は全身性エリテマトーデスであることを特徴とする請求項13記載の自己免疫疾病治療に用いる医薬組成物としている。
請求項15の発明は、自己免疫疾病治療に用いる医薬組成物は少なくとも有効剤量の請求項6記載の化合物と医学上受け入れ可能なキャリアを含むことを特徴とする自己免疫疾病治療に用いる医薬組成物としている。
請求項16の発明は、前記自己免疫疾病は全身性エリテマトーデスであることを特徴とする請求項15記載の自己免疫疾病治療に用いる医薬組成物としている。
そのテストのステップは以下に詳述する。
Claims (13)
- 化合物 4−ハイドロキシ−2,3−ジメトキシ−6−メチル−5(3,7,11−トリメチル−ドデカ−2,6,10−トリエニル)−シクロヘキセ−2−エンオン(4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11- trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone)を含む、自己免疫疾病の治療に用いる医薬組成物。
- 前記化合物はベニクスノキタケの有機溶剤抽出物中から分離製造することを特徴とする請求項1記載の医薬組成物。
- 前記有機溶剤はメタノール、エタノール、プロパノール、アセチジン、ヘキサン、クロロメタン、およびエチルクロライドからなるグループから選択することを特徴とする請求項2記載の医薬組成物。
- 前記有機溶媒はエタノールであることを特徴とする請求項3記載の医薬組成物。
- 前記化合物はベニクスノキタケの水抽出物中より分離製造することを特徴とする請求項1記載の医薬組成物。
- 自己免疫疾病が哺乳動物において引き起こす腎臓損傷、及び抗核抗体が器官および組織において引き起こす傷害を、緩和可能であることを特徴とする請求項1〜5のいずれか1項記載の医薬組成物。
- 前記哺乳動物はヒトであることを特徴とする請求項6記載の医薬組成物。
- 前記自己免疫疾病は全身性エリテマトーデスであることを特徴とする請求項7記載の医薬組成物。
- 哺乳動物の尿タンパク含量を低下させることにより、全身性エリテマトーデスが引き起こす腎臓損傷を緩和することができることを特徴とする請求項8記載の医薬組成物。
- 哺乳動物血清中の抗核抗体含量を低下させ、システム性エリテマトーデスが引き起こす自己組織器官への損傷を緩和することができることを特徴とする請求項8記載の医薬組成物。
- 前記抗核抗体はダブルストランドDNAの抗核抗体であることを特徴とする請求項10記載の医薬組成物。
- 少なくとも、請求項1に定義した化合物と医学上受け入れ可能なキャリアとを含むことを特徴とする自己免疫疾病治療に用いる医薬組成物。
- 前記自己免疫疾病は全身性エリテマトーデスであることを特徴とする請求項12記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007184470A JP5203644B2 (ja) | 2007-07-13 | 2007-07-13 | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007184470A JP5203644B2 (ja) | 2007-07-13 | 2007-07-13 | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009019020A JP2009019020A (ja) | 2009-01-29 |
JP5203644B2 true JP5203644B2 (ja) | 2013-06-05 |
Family
ID=40358980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007184470A Active JP5203644B2 (ja) | 2007-07-13 | 2007-07-13 | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5203644B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9144520B2 (en) | 2011-07-14 | 2015-09-29 | Gideon Mor | Noninvasive detection of meconium in amniotic fluid |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI394573B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
TWI452032B (zh) * | 2011-01-21 | 2014-09-11 | Golden Biotechnology Corp | 治療腎病之醫藥組成物 |
CN104857029A (zh) * | 2015-05-13 | 2015-08-26 | 柳州市耕青科技有限公司 | 一种用于过敏性皮炎的牛樟芝药物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3540089B2 (ja) * | 1996-03-01 | 2004-07-07 | ポーラ化成工業株式会社 | 抗体産生細胞抑制増強剤及びそれを含有する組成物 |
JPH11130690A (ja) * | 1997-10-29 | 1999-05-18 | Miyato Higaki | 免疫調節薬及び抗炎症薬 |
JP2003073298A (ja) * | 2001-09-04 | 2003-03-12 | Fumiharu Eguchi | 免疫調整剤 |
TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
TWI394573B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
TWI394575B (zh) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
-
2007
- 2007-07-13 JP JP2007184470A patent/JP5203644B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9144520B2 (en) | 2011-07-14 | 2015-09-29 | Gideon Mor | Noninvasive detection of meconium in amniotic fluid |
Also Published As
Publication number | Publication date |
---|---|
JP2009019020A (ja) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI394572B (zh) | Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases | |
JP5085222B2 (ja) | B型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキサンケトン化合物 | |
CN101357883B (zh) | 治疗自体免疫疾病的牛樟芝环己烯酮化合物及医药组成物 | |
JP5085186B2 (ja) | ベニクスノキタケから単離された新規化合物 | |
JP5014959B2 (ja) | ベニクスノキタケ抽出物から分離させた新化合物 | |
KR101069959B1 (ko) | 안트로디아 캄포라타로부터 얻은 시클로헥세논 유형의 간보호 화합물 | |
EP2246047B1 (en) | Use of lanostane derivatives in treating cachexia | |
WO2009052711A1 (fr) | Nouveaux composés isolés d'un extrait d'antrodia camphorata | |
WO2008089674A1 (fr) | Cyclohexénone extraite d'antrodia camphorata | |
TWI394566B (zh) | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds | |
JP5203644B2 (ja) | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 | |
TW201102075A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer | |
TW201109023A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of colorectal cancer | |
TW201109013A (en) | Cyclohexenone chemical compounds of Antrodia cinnamomea for suppressing the growth of the Lymphoma tumor cell | |
TWI383790B (zh) | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds | |
TW201109024A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of bladder cancer | |
TW201034657A (en) | Cyclohexene compound | |
EP2651389B1 (en) | Terpenoid spiro ketal compounds with lxr agonists activity, their use and formulations with them | |
TWI432203B (zh) | 以羊毛固醇及茯苓萃取物治療惡病質的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20120214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120606 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120606 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5203644 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |